Alveus Therapeutics

Alveus Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation therapies for obesity and metabolic diseases, aiming to achieve sustained efficacy, improved tolerability, and reduced treatment burden. Alveus Therapeutics' leading program, ALV-100, is a bifunctional fusion protein that acts as both a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and a glucagon-like peptide-1 receptor (GLP-1R) agonist. This fusion protein is designed to provide potent, long-lasting weight loss and maintenance effects while improving tolerability, addressing the major limitations of current chronic treatments.